Corrigendum to "Striatal dopaminergic D2 receptor occupancy & clinical efficacy in psychosis exacerbation: A 1231-IBZM study with ziprasidone and haloperidol" [Progress in Neuro-Psychopharmacology and Biological Psychiatry 29 (2005) 91-96] (DOI:10.1016/j.pnpbp.2004.10.010);Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: A 123I-IBZM study with ziprasidone and haloperidol

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 29, Issue 1, 2005, Pages 91-96

  Corripio, Iluminada ^a   Catafau, Ana M ^a   Perez, Víctor ^a   Puigdemont, Dolors ^a   Mena, Esther ^a   Aguilar, Yolanda ^a   Carrió, Ignasi ^a   Álvarez, Enric ^a  

^a Hosp Sta Creu I St Pau C/ Sant A Spain ^*  (Spain)

Author keywords

Antipsychotics; Dopaminergic receptors; Extrapyramidal side effects; Haloperidol; IBZM SPECT; Schizophrenia; Ziprasidone

Indexed keywords

DOPAMINE 2 RECEPTOR; HALOPERIDOL; ZIPRASIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MEGADOSE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; POSITIVE SYNDROME; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECEPTOR OCCUPANCY; SINGLE BLIND PROCEDURE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 10944267670     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.04.010     Document Type: Erratum

References (38)

1. American Psychiatric Association Press DSM: IV. Diagnostic and Statistical Manual of Mental Disorders 4th ed. Revised 1994 American Psychiatry Association Press Washington, DC
2. L. Arborelius, K. Chergui, S. Murase, G.G. Nomitos, B.B. Hook, G. Chouvet, U. Hacksell, and T.H. Svensson The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons Naunyn-Schmiedeberg's Arch. Pharmacol. 347 1993 353 362
3. C.J. Bench, A.A. Lammertsma, R.J. Dolan, P.M. Grasby, S.J. Warrington, K. Gunn, M. Cuddigan, D.J. Turton, S. Osman, and R.S. Frackowiak Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride Psychopharmacology 112 1993 308 314
4. V. Bigliani, R.S. Mulligan, P.D. Acton, R.I. Ohlsen, V.W. Pike, P.J. Ell, S. Gacinovic, R.W. Kerwin, and L.S. Pilowsky Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I] epidepride single photon emission tomography (SPECT) study Psychopharmacology 150 2000 132 140
5. D.G. Daniel, D.L. Zimbroff, S.G. Potkin, K.R. Reeves, E.P. Harrigan, and M. Lakshminarayanan Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone study group Neuropsychopharmacology 20 1999 491 505
6. L. Farde, A.L. Nordstrom, F.A. Wiesel, S. Pauli, C. Halldin, and G. Sedvall Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects Arch. Gen. Psychiatry 49 1992 538 544
7. D.C. Goff, T. Posever, L. Herz, J. Simmons, N. Kletti, K. Lapierre, K.D. Wilner, C.G. Law, and G.N. Ko An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder J. Clin. Psychopharmacol. 18 1998 296 304
8. J. Guardia, A.M. Catafau, F. Batlle, J.C. Martín, B. Gonzalvo, L. Segura, G. Prat, I. Carrió, and M. Casas Striatal dopaminergic D2 receptor density measured by [123I]Iodobenzamide SPECT in the prediction of treatment outcome of alcohol-dependent patients Am. J. Psychiatry 157 2000 127 129
9. J.D. Jentsch, and R.H. Roth The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia Neuropsychopharmacology 20 1999 201 225
10. S. Kapur, and P. Seeman Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis Am. J. Psychiatry 158 2001 360 369
11. S. Kapur, G. Remington, R.B. Zipursky, A.A. Wilson, and S. Houle The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study Life Sci. 57 1995 103 107
12. S. Kapur, G. Remington, C. Jones, A. Wilson, J. DaSilva, S. Houle, and R. Zipursky High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study Am. J. Psychiatry 153 1996 948 950
13. S. Kapur, R.B. Zipursky, and G. Remington Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia Am. J. Psychiatry 156 1999 286 293
14. S. Kapur, R. Zipursky, C. Jones, G. Remington, and S. Houle Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia Am. J. Psychiatry 157 2000 514 520
15. S.R. Kay, A. Fiszbein, and L.A. Opler The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr. Bull. 13 1987 261 276
16. P. Keck Jr., A. Buffenstein, J. Ferguson, J. Feighner, W. Jaffe, E.P. Harrigan, and M.R. Morrissey Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial Psychopharmacology 140 1998 173 184
17. P.E. Keck Jr., K.R. Reeves, and E.P. Harrigan Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies J. Clin. Psychopharmacol. 21 2001 27 35
18. B.J. Kinon, and J.A. Lieberman Mechanisms of action of atypical antipsychotic drugs: a critical analysis Psychopharmacology 124 1996 2 34
19. E. Klemm, F. Grunwald, S. Kasper, C. Menzel, K. Broich, P. Danos, K. Reichmann, C. Krappel, O. Rieker, B. Briele, A.L. Hotze, H.J. Moller, and H.J. Biersack [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics Am. J. Psychiatry 153 1996 183 190
20. M.B. Knable, A. Heinz, T. Raedler, and D.R. Weinberger Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels Psychiatry Res. 75 1997 91 101
21. B. Kufferle, J. Tauscher, S. Asenbaum, C. Vesely, I. Podreka, T. Brucke, and S. Kasper IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol Psychopharmacology 133 1997 323 328
22. M. Laruelle, A. Abi-Dargham, R. Gil, L. Kegeles, and R. Innis Increased dopamine transmission in schizophrenia: relationship to illness phases Biol. Psychiatry 46 1999 56 72
23. D. Mamo, S. Kapur, C.M. Shammi, G. Papatheodorou, S. Mann, F. Therrien, and G. Remington A PET study of dopamine D(2) and serotonin 5-HT(2) receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone Am. J. Psychiatry 161 2004 818 825
24. H.Y. Meltzer, Z. Li, Y. Kaneda, and J. Ichikawa Serotonin receptors: their key role in drugs to treat schizophrenia Prog. Neuro-psychopharmacol. Biol. Psychiatry 27 2003 1159 1172
25. A.L. Nordstrom, L. Farde, F.A. Wiesel, K. Forslund, S. Pauli, C. Halldin, and G. Uppfeldt Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients Biol. Psychiatry 33 1993 227 235
26. V. Perez, A. Catafau, I. Corripio, J.C. Martín, and E. Alvarez Preliminary evidence of striatal D2 receptor density as a possible biological marker of prognosis in naive schizophrenic patients Prog. Neuro-psychopharmacol. Biol. Psychiatry 27 2003 767 770
27. L.S. Pilowsky, D.C. Costa, P.J. Ell, R.M. Murray, N.P. Verhoeff, and R.W. Kerwin Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia Lancet 340 1992 199 202
28. L.S. Pilowsky, D.C. Costa, P.J. Ell, R.M. Murray, N.P. Verhoeff, and R.W. Kerwin Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study Psychol. Med. 23 1993 791 797
29. L.S. Pilowsky, R.S. Mulligan, P.D. Acton, P.J. Ell, D.C. Costa, and R.W. Kerwin Limbic selectivity of clozapine Lancet 350 1997 490 491
30. G. Remington, and S. Kapur Atypical antipsychotics: are some more atypical than others? Psychopharmacology 148 2000 3 15
31. V. Sharma Clozapine current status and role in the pharmacotherapy of schizophrenia Can. J. Psychiatry 41 1996 483
32. G.M. Simpson, and J.W. Angus A rating scale for extrapyramidal side effects Acta Psychiatr. Scand., Suppl. 212 1970 11 19
33. G.L. Stimmel, M.A. Gutierrez, and V. Lee Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia Clin. Ther. 24 2002 21 37
34. K. Tatsch, S. Asenbaum, P. Bartenstein, A. Catafau, C. Halldin, L.S. Pilowsky, and A. Pupi European association of nuclear medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) receptor ligands Eur. J. Nucl. Med. Mol. Imaging 29 2002 23 29
35. J. Tauscher, B. Kufferle, S. Asenbaum, S. Tauscher-Wisniewski, and S. Kasper Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol Psychopharmacology 162 2002 42 49
36. F.M. Van Der Heijden, S. Tuinier, D. Fekkes, A.E. Sijben, R.S. Kahn, and W.M. Verhoeven Atypical antipsychotics and the relevance of glutamate and serotonin Eur. Neuropsychopharmacol. 14 2004 259 265
37. World Medical Association Declaration of Helsinki, 5th (Edinburgh) amendment. October 2000.
38. X. Xiberas, J.L. Martinot, L. Mallet, E. Artiges, C. Loc'H, B. Maziere, and M.L. Paillere-Martinot Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia Br. J. Psychiatry 179 2001 503 508